1-butoxyimidazole | 1109225-07-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-butoxyimidazole
• 英文别名: 1-Butoxyimidazole
• CAS: 1109225-07-1
• 化学式: C₇H₁₂N₂O
• 分子量: 140.185
• InChiKey: QYRLMJYNMLGDLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-butoxyimidazole 、 溴甲苯 以 乙腈 为溶剂， 反应 72.0h， 以95%的产率得到3-benzyl-1-butyloxyimidazolium bromide
  参考文献：
  名称：

  Laus, Gerhard; Schwaerzler, Alexander; Bentivoglio, Gino, Zeitschrift fur Naturforschung, B: Chemical Sciences, 2008, vol. 63, # 4, p. 447 - 464

  摘要：

  DOI：

文献信息

• [EN] IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST<br/>[FR] DÉRIVÉS D'IMIDAZO[2,1-F] [1, 2, 4] TRIAZIN-4-AMINE UTILISÉS EN TANT QU'AGONISTES DE TLR7
  申请人：BEIGENE LTD

  公开号：WO2020160711A1

  公开（公告）日：2020-08-13

  Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.

  披露的是一种咪唑[2,1-f][1,2,4]三嗪-4-胺衍生物或其立体异构体，或其药用可接受盐，用作TLR7激动剂，以及包含该化合物的药物组合物。还披露了一种使用咪唑[2,1-f][1,2,4]三嗪-4-胺衍生物或其立体异构体，或其药用可接受盐作为TLR7激动剂来治疗癌症的方法。
• [EN] THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS<br/>[FR] DÉRIVÉS DE LA THIÉNO [2, 3-B] PYRIDINE EN TANT QU'INHIBITEURS DE RÉPLICATION VIRALE
  申请人：UNIV LEUVEN KATH

  公开号：WO2010130842A1

  公开（公告）日：2010-11-18

  The present invention relates to a series of compounds of formula (A) having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

  本发明涉及一系列具有抗病毒活性的化合物(A)的公式，更具体地说是具有抑制HIV（人类免疫缺陷病毒）复制的特性。该发明还涉及制备这类化合物的方法，以及在这类合成的一个或多个步骤中有用的新中间体。该发明还涉及包含有效量这类化合物作为活性成分的药物组合物。本发明进一步涉及将这类化合物用作药物或用于制造用于治疗患有病毒感染的动物，尤其是HIV感染的药物。本发明还涉及通过给予这类化合物的治疗量，可选地与一个或多个具有抗病毒活性的其他药物结合，来治疗动物的病毒感染的方法。
• THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS
  申请人：Katholieke Universiteit Leuven

  公开号：US20140296272A1

  公开（公告）日：2014-10-02

  The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

  本发明涉及一系列具有抗病毒活性的化合物，更具体地说是具有抑制HIV（人类免疫缺陷病毒）复制的性质。 本发明还涉及制备这种化合物的方法，以及在这些合成步骤中有用的新型中间体。 本发明还涉及包含有效量这种化合物作为活性成分的制药组合物。 本发明还涉及使用这种化合物作为药物或制造用于治疗患有病毒感染的动物，特别是HIV感染的药物。 本发明还涉及通过给予这种化合物的治疗量治疗动物的病毒感染的方法，可选择地与一个或多个具有抗病毒活性的其他药物结合使用。
• IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST
  申请人：BeiGene, Ltd.

  公开号：EP3921320A1

  公开（公告）日：2021-12-15
• US8785638B2
  申请人：——

  公开号：US8785638B2

  公开（公告）日：2014-07-22